Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
Sen Han,1 Jian Fang,1 Shun Lu,2 Linfang Wang,3 Jing Li,3 Min Cheng,3 Yongxin Ren,3 Weiguo Su3 1Department of Thoracic Oncology Ii, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China; 2Sha...
Main Authors: | Han S, Fang J, Lu S, Wang L, Li J, Cheng M, Ren Y, Su W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/response-and-acquired-resistance-to-savolitinib-in-a-patient-with-pulm-peer-reviewed-article-OTT |
Similar Items
-
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer
by: Limei YIN, et al.
Published: (2018-07-01) -
MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
by: Xue-wen Liu, et al.
Published: (2020-12-01) -
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2021-03-01) -
Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
by: Masaya Nishino, et al.
Published: (2021-05-01) -
Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)